Enzymatica publ AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Enzymatica publ AB Announces Positive Results from COLDPREV Clinical Pilot Study
Enzymatica publ AB announced that the Company has reached positive results from a clinical pilot study on 46 individuals performed at the Ear, Nose and Throat Clinic at Skane University Hospital in Lund, Sweden. In individuals who were infected with the common cold virus, ColdZyme Mouth Spray reduced both the viral load and the number of sick days with a cold compared with placebo. COLDPREV – which was performed during the spring at the Ear, Nose and Throat Clinic at Skane University Hospital – is a randomized, double-blind, placebo-controlled clinical pilot study for ColdZyme Mouth Spray medical device. In this study 46 subjects, both men and women (aged 20-46), were inoculated (infected) with the common cold virus (rhinovirus) via the nose. Despite the study being a pilot study, aimed at providing a basis for larger studies, a difference was found between ColdZyme and placebo with regard to reduction of the viral load in the throat (-99%) and reduction in the number of days with a cold (-54%).
Latest Developments for Enzymatica publ AB
Latest Key Developments in Food
- La Doria SpA proposes FY 2013 dividend; issues FY 2014 outlook in-line with estimates
- General Mills Inc reaffirms FY 2014 EPS outlook; gives Q3 2014 EPS outlook below analysts' estimates; gives Q4 2014 EPS outlook
- Sunjuice Holdings announces FY 2013 dividend payment
- Kee Song Bio-Technology Holdings announces FY 2013 dividend payment
- Share this
- Digg this